{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=100",
    "query": {
      "condition": "Phase I",
      "page": 100
    },
    "page_size": 10
  },
  "pagination": {
    "page": 100,
    "page_size": 10,
    "total_count": 18757,
    "total_pages": 1876,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=101&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=99&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-13T23:55:45.894Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03096080",
      "title": "A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Polycystic Kidney, Autosomal Recessive"
      ],
      "interventions": [
        {
          "name": "Tesevatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kadmon Corporation, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "5 Years to 12 Years"
      },
      "enrollment_count": 10,
      "start_date": "2017-08-24",
      "completion_date": "2019-09-30",
      "has_results": false,
      "last_update_posted_date": "2022-05-11",
      "last_synced_at": "2026-11-13T23:55:45.894Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03096080"
    },
    {
      "nct_id": "NCT07725380",
      "title": "Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma",
        "Osteosarcoma"
      ],
      "interventions": [
        {
          "name": "Domatinostat",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 74,
      "start_date": "2026-07-15",
      "completion_date": "2031-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-11-13T23:55:45.894Z",
      "location_count": 4,
      "location_summary": "Tampa, Florida • St Louis, Missouri • The Bronx, New York + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07725380"
    },
    {
      "nct_id": "NCT06529796",
      "title": "Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Focal Segmental Glomerulosclerosis (FSGS)"
      ],
      "interventions": [
        {
          "name": "IXP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 36,
      "start_date": "2024-08-02",
      "completion_date": "2024-12-20",
      "has_results": false,
      "last_update_posted_date": "2025-01-20",
      "last_synced_at": "2026-11-13T23:55:45.894Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • St. Petersburg, Florida • San Antonio, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06529796"
    },
    {
      "nct_id": "NCT03286296",
      "title": "LZM009 to Treat Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Livzon Pharmaceutical Group Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2017-08-21",
      "completion_date": "2019-04-23",
      "has_results": false,
      "last_update_posted_date": "2019-08-02",
      "last_synced_at": "2026-11-13T23:55:45.894Z",
      "location_count": 2,
      "location_summary": "Grand Rapids, Michigan • San Antonio, Texas",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03286296"
    },
    {
      "nct_id": "NCT07602855",
      "title": "A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms, Lung"
      ],
      "interventions": [
        {
          "name": "Risvutatug rezetecan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ivonescimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 184,
      "start_date": "2026-09-09",
      "completion_date": "2029-12-24",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-11-13T23:55:45.894Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Wilson, North Carolina • Canton, Ohio",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Wilson",
          "state": "North Carolina"
        },
        {
          "city": "Canton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07602855"
    },
    {
      "nct_id": "NCT05153408",
      "title": "(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Neoplasm",
        "Carcinoma, Non-Small-Cell Lung",
        "Respiratory Tract Neoplasms",
        "Neoplasms",
        "Neoplasms by Site",
        "Lung Diseases",
        "Respiratory Tract Diseases",
        "Carcinoma, Bronchogenic",
        "Bronchial Neoplasms",
        "Adenocarcinoma",
        "Carcinoma",
        "Neoplasms by Histologic Type",
        "Neoplasms, Nerve Tissue",
        "EGFR C797S",
        "EGFR C797A",
        "EGFR L858R",
        "EGFR Exon 19 Deletion",
        "EGFR Gene Mutation",
        "EGF-R Positive Non-Small Cell Lung Cancer",
        "EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance",
        "EGFR Activating Mutation",
        "Thoracic Neoplasms",
        "Antineoplastic Agents",
        "Protein Kinase Inhibitors",
        "EGFR C797G",
        "EGFR C797X",
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "BLU-701",
          "type": "DRUG"
        },
        {
          "name": "osimertinib",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Blueprint Medicines Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2022-01-13",
      "completion_date": "2022-12-09",
      "has_results": false,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-11-13T23:55:45.894Z",
      "location_count": 7,
      "location_summary": "Boston, Massachusetts • Detroit, Michigan • New York, New York + 3 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05153408"
    },
    {
      "nct_id": "NCT01208974",
      "title": "Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Ductal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Nipple-Sparing Mastectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Breast Reconstruction",
          "type": "PROCEDURE"
        },
        {
          "name": "Axillary Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Prophylactic Nipple-Areolar Complex RT",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 21,
      "start_date": "2010-03-16",
      "completion_date": "2026-05-31",
      "has_results": true,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-11-13T23:55:45.894Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01208974"
    },
    {
      "nct_id": "NCT01013818",
      "title": "A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoid Malignancies"
      ],
      "interventions": [
        {
          "name": "HGS1029",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Human Genome Sciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2009-10",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2013-08-02",
      "last_synced_at": "2026-11-13T23:55:45.894Z",
      "location_count": 2,
      "location_summary": "Rochester, Minnesota • Hackensack, New Jersey",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01013818"
    },
    {
      "nct_id": "NCT07090590",
      "title": "Evaluating Feasibility, Acceptability, Usability, and an Initial Estimate of Effect of a Novel Training Platform on Peer Recovery Supporter Skill, Adherence, and Knowledge Gain-Phase I",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Substance-related Disorders",
        "Alcohol and Other Substance Use Prevention",
        "Alcohol and Other Drug Use Disorders"
      ],
      "interventions": [
        {
          "name": "Thrive Digital Peer Platform (TDPP)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Thrive Digital Health, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2024-03-18",
      "completion_date": "2024-08-31",
      "has_results": false,
      "last_update_posted_date": "2025-07-29",
      "last_synced_at": "2026-11-13T23:55:45.894Z",
      "location_count": 1,
      "location_summary": "Solon, Ohio",
      "locations": [
        {
          "city": "Solon",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07090590"
    },
    {
      "nct_id": "NCT02029690",
      "title": "Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pleural Mesothelioma Malignant Advanced",
        "Peritoneal Mesothelioma Malignant Advanced",
        "Non-squamous Non-small Cell Lung Carcinoma",
        "Uveal Melanoma",
        "Hepatocellular Carcinoma",
        "Glioma",
        "Sarcomatoid Carcinoma"
      ],
      "interventions": [
        {
          "name": "ADI-PEG 20",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Polaris Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2014-04-23",
      "completion_date": "2020-06",
      "has_results": false,
      "last_update_posted_date": "2020-09-25",
      "last_synced_at": "2026-11-13T23:55:45.894Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02029690"
    }
  ]
}